Morningstar

J&J’s Drug Pipeline Not Strong Enough to Accelerate Growth

Increasing commotion over its branded drugs and a device segment that seems to lack innovation will hold back J&J’s revenue growth in the coming years.

 and
Securities In This Article
Johnson & Johnson
(JNJ)

In the quarter, after adjusting for several factors (acquisitions, divestitures, foreign exchange rates, and the hepatitis C sales declines), J&J posted 5% year-over-year growth led by drug sales. While we believe the 5% growth number is the best representation of underlying growth, the multiple adjustments to sales and earnings slightly reduces the quality of the reported growth rate. Going forward, we expect the growth rate of J&J to slow as pipeline products lack enough potential to offset increasing generic and branded competition. In particular, we expect increased generic and biosimilar pressure on hard to make drugs Risperdal Consta, Invega Sustenna, Procrit and Remicade (14% of sales in aggregate). Despite these pressures, several recently launched drugs, including diabheadwindsetes drug Invokana and cardiovascular drug Xarelto, should help mitigate .

Outside of the drug space, we expect the strength in J&J's consumer business to continue to offset slower growth in the medical device segment. J&J's improvement in manufacturing quality and stronger pricing power in vision care products should continue to improve consumer sales, which were up 3% year over year. However, we remain less optimistic regarding the slow growing medical device group (up only 1% in the quarter), which seems to lack innovative product development.

Morningstar Premium Members gain exclusive access to our full Analyst Reports, including fair value estimates, consider buying/selling prices, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

More in Stocks

Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue

Estee Lauder, Kraft Heinz, and Dollar General are our top consumer defensive stocks.
Erin Lash, CFA

Industrials: Many Stocks Overvalued After Q3 Outperformance

Our top stocks in this sector are Chart Industries, Wesco, and CNH Industrial.
Brian Bernard, CFA, CPA

Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities

In this sector, our favored stocks are Albemarle, Dow, and FMC.
Andrew Bischof, CFA and Travis Miller

About the Authors

Damien Conover, CFA

Director of Equity Research, North America
More from Author

Damien Conover, CFA, is director of equity research, North America, for Morningstar*.

Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.

Conover holds bachelor’s and master’s degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.

* Morningstar Research Services LLC (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc

Alex Morozov, CFA

Regional Director
More from Author

Alex Morozov, CFA, is a regional director, Europe, for Morningstar*. He leads a team of equity analysts based in Europe who cover European and global companies across all major sectors of the economy. Morozov is also a member of the Equity Research leadership group and a member of the Economic Moat Committee. In addition to leading the European analyst team, reviewing ratings recommendations, and developing talent, Morozov also leads business development efforts in Europe, working closely with the institutional sales team and media/marketing partners.

Before joining Morningstar in 2006, Morozov worked in the insurance industry. Before assuming his current role in 2014, Morozov was head of global healthcare equity research. Previously, he was a senior equity analyst, covering the medical instruments, life sciences, and diagnostics industries.

Morozov holds a bachelor’s degree in finance, with a minor in mathematics, from the University of Missouri. He also holds the Chartered Financial Analyst® designation. Morozov was the member of the Board for the CFA Society of Netherlands from 2020-2024.

*Morningstar Holland BV (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc

Sponsor Center